Jericho Capital Asset Management L.P. Zai Lab LTD Transaction History

Jericho Capital Asset Management L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$27.77 - $64.4 $2.36 Million - $5.47 Million	-85,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$54.9 - $105.21 $2.47 Million - $4.73 Million	-45,000 Reduced 34.62%	85,000 $5.34 Million
Q3 2021 Nov 15, 2021	BUY	$105.0 - $178.37 $2.21 Million - $3.75 Million	21,000 Added 19.27%	130,000 $13.7 Million
Q1 2021 May 17, 2021	SELL	$126.27 - $191.71 $3.66 Million - $5.56 Million	-29,000 Reduced 21.01%	109,000 $14.5 Million
Q4 2020 Feb 16, 2021	BUY	$81.94 - $135.34 $1.07 Million - $1.76 Million	13,000 Added 10.4%	138,000 $18.7 Million
Q3 2020 Nov 16, 2020	BUY	$73.3 - $89.48 $1.25 Million - $1.52 Million	17,000 Added 15.74%	125,000 $10.4 Million
Q2 2020 Aug 14, 2020	BUY	$48.82 - $82.53 $5.27 Million - $8.91 Million	108,000 New	108,000 $8.87 Million

116

40.8M

63.1K

420K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.96B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Jericho Capital Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Jericho Capital Asset Management L.P. with notifications on news.